Sunovion and BIAL enter European licensing agreement for Apomorphine Sublingual Film


Deprecated: strlen(): Passing null to parameter #1 ($string) of type string is deprecated in /home/medicircle/public_html/script_newsdetails.php on line 75
▴
Latest Pharma Updates

Sunovion Pharmaceuticals Inc. announced that it has entered into an agreement with BIAL in which Sunovion has granted exclusive commercial license rights in Europe for apomorphine sublingual film (APL-130277). APL-130277, approved as KYNMOBI (apomorphine hydrochloride) sublingual film in the U.S. and Canada, is a novel thin film formulation of apomorphine that dissolves under the tongue for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). APL-130277 is currently in Phase 3 clinical development in Europe.

By 2030, an estimated 10 million people worldwide will be living with PD.1 OFF episodes are the re-emergence or worsening of PD symptoms otherwise controlled with oral levodopa/carbidopa. These episodes may disrupt a person’s ability to perform everyday activities and are characterized, in part, by tremor, stiffness, slowed movement or other symptoms.

Under the terms of the agreement, BIAL will be responsible for submitting marketing applications consistent with marketing authorization procedures in Europe and have exclusive commercial rights to distribute and commercialize apomorphine sublingual film in the European Union (EU), the European Economic Area (EEA) as well as the United Kingdom. BIAL expects to submit a European marketing authorization application for apomorphine sublingual film by the end of 2021. Sunovion will receive an upfront payment and is entitled to receive certain milestone payments. Sunovion will supply KYNMOBI in all approved dose strengths to BIAL.

Sunovion continues to hold the exclusive commercial rights to KYNMOBI in North America and all other regions of the world outside of the EU, EEA as well as the United Kingdom. KYNMOBI is the first and only sublingual (under the tongue) therapy available for the on-demand treatment of PD OFF episodes in the U.S. and Canada.

Tags : #Apomorphine #Sunovion #BIAL #ParkinsonsDisease

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

Digital Identity Fraud in Healthcare: What India Must KnowNovember 18, 2026
Wearables in Clinical Care: When Should Doctors Trust the Data?November 18, 2026
Cybersecurity for Medical Startups: What Founders MissNovember 18, 2026
Remote Patient Monitoring: The Next Phase of Virtual CareNovember 18, 2026
Digital Health Wallets: Future of Medical Records in IndiaNovember 17, 2026
How Hospitals Can Prepare for a Transparent Healthcare MarketNovember 17, 2026
Childhood Nutrition: Understanding Micronutrient Gaps Beyond CaloriesNovember 16, 2026
Anaemia in Adolescent Girls: Connecting Prevention, Testing and Nutrition SupportNovember 16, 2026
Health Information Exchanges in India: Are Medical Records Finally Going Portable?November 16, 2026
Hospital Accreditation in 2026: What Is Changing Beyond the Checklist?November 16, 2026
Digital Insurance Platforms and India's Health Coverage FutureNovember 14, 2026
ABDM 2.0: India's Digital Health Ecosystem FutureNovember 14, 2026
Vaccine Cold-Chain Management: Protecting Immunisation Quality From Storage to DeliveryNovember 14, 2026
Foodborne Illness Surveillance: How Public Health Systems Track RisksNovember 14, 2026
Interoperability in Indian Healthcare: Why Patient Data Still StrugglesNovember 13, 2026
Tuberculosis Contact Screening: How Preventive Care Works Around ExposureNovember 13, 2026
COPD Care in India: Linking Diagnosis, Inhaler Education and Follow-UpNovember 13, 2026
Management of ANCA Glomerulonephritis: Induction & Maintenance ProtocolsNovember 12, 2026
Smart Hospital Command Centres Transforming IndiaNovember 12, 2026
Gamma Knife Surgery in India: What You Need to KnowNovember 12, 2026